BioWorld Asia

April 10, 2002

Amrad Drugs Dropped By GlaxoSmithKline, DevoCo

SYDNEY, Australia - Melbourne-based Amrad Ltd. blamed a general industry shift into late-stage research projects on the decision by GlaxoSmithKline plc and DevoCo Pharmaceuticals Ltd. to separately abandon development work on Amrad compounds. (BioWorld International) Read More

Ark IPO Aims For £40M, Looks To End UK Public Offering Dry Spell

Zealand Pharmaceuticals Moves ZP120 Into Phase I Development

RiboTargets Signs With ICR To Develop Inhibitors Of HSP90

Australian Governments Agree On Stems Cells; Senate Must OK

Other News To Note

Correction

Evologic Uses Forced Evolution To Create Microbial Organisms

Today's news in brief

BioWorld

BioWorld briefs for July 2, 2026.

CINP 2026: Prenatal and adolescent stress shape brain vulnerability

BioWorld Science

Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...

Ontrack Therapeutics divulges compounds for neurodegenerative diseases

BioWorld Science

Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.

Modius Spero wearable neuromodulation device

Neurovalens granted FDA approval for PTSD therapy for US veterans

BioWorld

Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...

Neuracle eyes Shanghai IPO as global BCI funding surges

BioWorld

Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...